Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Debu Tripathy, Ricardo H. Alvarez, Rashmi Krishna Murthy, Naoto T. Ueno, Carlos H. Barcenas, Jimin Wu, Jangsoon Lee, Richard Piekarz, Toshiaki Iwase, S. Jackson, Stacy L. Moulder, Sharon H. Giordano, Jeffrey A. Moscow, Abenaa M. Brewster, Vicente Valero, Darren W. Davis, Jie Willey, Nuhad K. Ibrahim, Yu Shen, Powel H. Brown, Bora Lim, Daniel J. Booser
Publikováno v:
British Journal of Cancer
Background Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, an HDAC inhibitor epigenetically revers
Autor:
Hyo S. Han, Michelle E. Melisko, Anne M. Wallace, Meredith Buxton, Rita Nanda, Claudine Isaacs, Michael Feldman, Brian Leyland-Jones, Sharon Sams, Erica Stringer-Reasor, Qamar J. Khan, Andres Forero-Torres, Anthony D. Elias, Idris Tolgay Ocal, Nola M. Hylton, Stefan E. Pambuccian, Rebecca K. Viscusi, Kathleen Kemmer, W. Fraser Symmans, Donald A. Berry, Tuyethoa Vinh, Husain Sattar, Jay Zeck, Paulette Mhawech-Fauceglia, Jeffrey B. Matthews, Gregor Krings, Olufunmilayo I. Olopade, Katherine Steeg, Lajos Pusztai, Laura J. Esserman, Shelly S. Lo, Kathy S. Albain, Amy S. Clark, Sunati Sahoo, Melissa Paoloni, Oluwole Fadare, Laura J. van't Veer, Julia L. Clennell, Anthony M. Magliocco, Amy Wilson, Jane Perlmutter, Shuko Harada, Julie E. Lang, David M. Euhus, A. Jo Chien, Heather Beckwith, Stephen Y. Chui, Shi Wei, Debasish Tripathy, Angela DeMichele, Erin D. Ellis, Molly Klein, Kathi Adamson, Garry Peterson, Gillian L. Hirst, Mara H. Rendi, Smita Asare, John W. Park, Minetta C. Liu, Judy C. Boughey, Richard Schwab, Douglas Yee, Lauren LeBeau, Ruby Singhrao, Ossama Tawfik, Stacy L. Moulder, Yunn Yi Chen, Kirsten K. Edmiston, Adam Asare, Janice Lu, Patricia Haugen, Donald W. Northfelt, Hope S. Rugo, Christina Yau, Ashish Sanil, Scott M. Berry, Brian Datnow, Teresa Helsten, Beiyun Chen
Publikováno v:
JAMA Oncol
Importance Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective T
Autor:
Gary J. Whitman, Joe Ensor, Andrew J. Bishop, Michael C. Stauder, Karen E. Hoffman, Mark A. Edson, Gildy Babiera, Sandra Whaley Bishnoi, Stacy L. Moulder, Thomas A. Buchholz, Vicente Valero, Simona F. Shaitelman, Wendy A. Woodward, Naoto T. Ueno
Publikováno v:
Cancer. 121:4324-4332
BACKGROUND This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained. METHODS This stu
Autor:
Debu Tripathy, Naoto T. Ueno, Jennifer K. Litton, Hong Zhang, Elizabeth A. Mittendorf, Sharon H. Giordano, Akshara Singareeka Raghavendra, Takeo Fujii, Bora Lim, Alastair M. Thompson, Mariana Chavez-MacGregor, Kenneth R. Hess, Vicente Valero, Carlos H. Barcenas, Rashmi Krishna Murthy, Stacy L. Moulder
Publikováno v:
Clinical breast cancer. 18(6)
Introduction Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2+) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic complete response (pCR) rate for trastuzu
Autor:
Christos Hatzis, Gabriel N. Hortobagyi, Stacy L. Moulder, Lajos Pusztai, Caimiao Wei, Rebekah Gould, Thomas A. Buchholz, Mei Liu, Maheshwari Ramineni, W. Fraser Symmans, Aman U. Buzdar, Xian Yu, Alex Bousamra, Kelly K. Hunt, Wei Yang, Bruno Valentin Sinn, Andrew Walls, Vicente Valero, Ya Zhang, Abenaa M. Brewster
Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)–targeted treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d532e7471bf031021f85ddc02ac522
https://europepmc.org/articles/PMC5455352/
https://europepmc.org/articles/PMC5455352/
Autor:
Jennifer J. Wheler, Christel C. Bastida, Yunfang Jiang, Gerald Steven Falchook, Stacy L. Moulder, Razelle Kurzrock
Publikováno v:
Annals of Oncology. 24:3004-3011
Preclinical data indicate that dual HER2 inhibition overcomes trastuzumab resistance and that use of an HER2 inhibitor with an anti-angiogenic agent may augment responses.We conducted a dose-escalation, phase I study of a combination of trastuzumab,
Autor:
Angela DeMichele, Teresa Helsten, Stephen Y. Chui, Christina Yau, Lajos Pusztai, Kathy S. Albain, W. Fraser Symmans, Ashish Sanil, Melissa Paoloni, Rebecca K. Viscusi, Anthony D. Elias, Sarah E. Davis, Debasish Tripathy, Kirsten K. Edmiston, Julia Lyandres, Nola M. Hylton, Laura J. Esserman, Michael Hogarth, Donald W. Northfelt, Laura J. van't Veer, Donald A. Berry, Meredith Buxton, Jane Perlmutter, A. Jo Chien, Gillian L. Hirst, John W. Park, Judy C. Boughey, Henry G. Kaplan, Minetta C. Liu, Stacy L. Moulder, Douglas Yee, Qamar J. Khan, Julie E. Lang, David M. Euhus, Tufia C. Haddad, William C. Wood, Richard Schwab, Michelle E. Melisko, Rita Nanda, Claudine Isaacs, Anne M. Wallace, Kathleen Kemmer, Barbara Haley
BackgroundThe heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b556d1a9a91a81ff185979e54f23a4
https://europepmc.org/articles/PMC5259558/
https://europepmc.org/articles/PMC5259558/
Autor:
R Ismail-Khan, S Modi, P. N. Munster, S Tangri, M Lucas, M Yamashita, CM Storgard, Stacy L. Moulder, Y Chen, GR Galluppi
Publikováno v:
Cancer Research. 70:P3-14
Background: BIIB021 is an oral, fully synthetic heat shock protein 90 inhibitor (Hsp90i) that selectively and potently inhibits the molecular chaperone Hsp90, thereby preventing proper assembly of oncogenic proteins such as HER2. Methods: The safety
Autor:
Marc C. Chamberlain, Alison Conlin, Erika Hamilton, Stacy L. Moulder, Todd Gray, Cristiano Ferrario, Ian E. Krop, Virginia F. Borges
Publikováno v:
Neuro-Oncology. 19:vi44-vi44